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Abstract
Background: Immunity against the bovine protozoan parasite Theileria parva has previously been
shown to be mediated through lysis of parasite-infected cells by MHC class I restricted CD8+
cytotoxic T lymphocytes. It is hypothesized that identification of CTL target schizont antigens will
aid the development of a sub-unit vaccine. We exploited the availability of the complete genome
sequence data and bioinformatics tools to identify genes encoding secreted or membrane anchored
proteins that may be processed and presented by the MHC class I molecules of infected cells to
CTL.
Results: Of the 986 predicted open reading frames (ORFs) encoded by chromosome 1 of the T.
parva genome, 55 were selected based on the presence of a signal peptide and/or a transmembrane
helix domain. Thirty six selected ORFs were successfully cloned into a eukaryotic expression
vector, transiently transfected into immortalized bovine skin fibroblasts and screened in vitro using
T. parva-specific CTL. Recognition of gene products by CTL was assessed using an IFN-γ ELISpot
assay. A 525 base pair ORF encoding a 174 amino acid protein, designated Tp2, was identified by
T. parva-specific CTL from 4 animals. These CTL recognized and lysed Tp2 transfected skin
fibroblasts and recognized 4 distinct epitopes. Significantly, Tp2 specific CD8+ T cell responses
were observed during the protective immune response against sporozoite challenge.
Conclusion: The identification of an antigen containing multiple CTL epitopes and its apparent
immunodominance during a protective anti-parasite response makes Tp2 an attractive candidate
for evaluation of its vaccine potential.
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Background
Theileria parva is a tick-transmitted haemoprotozoan par-
asite that causes an acute and often fatal disease of cattle
termed East Coast fever (ECF). ECF continues to be a
major threat to smallholder farmers in eastern, central
and southern Africa. There are at least 28 million cattle at
risk, over one million animals die each year, and annual
economic losses are estimated to be US$ 189 million [1].
The multinucleate schizont stage of the parasite has the
remarkable ability to transform the host lymphocytes it
infects into a state of uncontrolled proliferation [2].
Whilst this allows the rapid propagation of the parasite it
also leads to pathology and ultimately death in suscepti-
ble animals [3]. Cattle can be immunized against infec-
tion by the simultaneous infection of animals using the
tick-derived infective sporozoite stage of the parasite and
treatment with long-acting tetracycline [4]. This infection
and treatment regime engenders a robust and long-lasting
protective immunity that is mediated by MHC class I
restricted CD8+ cytotoxic T lymphocytes (CTL) directed
against the schizont-infected lymphocyte [5-7].
The post-genomics era offers an opportunity to develop
new strategies for vaccine development. In particular,
there has been a paradigm shift in the approach to antigen
discovery as highlighted by the use of the complete
genome sequence of Neisseria meningitidis to identify and
test a list of candidate vaccine antigens against meningo-
coccal meningitis [8]. The success of this approach,
termed 'reverse vaccinology' coupled with the ever-grow-
ing number of bacterial and protozoan genomes being
sequenced has allowed this concept to be extended to
other pathogens [9-11]. Successful application of reverse
vaccinology is dependent upon the availability of a high-
throughput system to test candidate antigens, but it has
been hampered by the lack of good in vitro correlates of
immunity. Protection from disease upon challenge in
small animal models is normally the only read-out avail-
able [12]. The correlation between the induction of CTL
responses and immunity to T. parva offered a system with
which to apply reverse vaccinology to a complex pathogen
where immunity was cell-mediated.
The strategy involved analyzing the genome to identify
genes encoding secreted or membrane bound proteins.
Since the genes were expressed by the intra-lymphocytic
schizont stage these proteins would be exposed to the host
cell cytosol and hence available for presentation to CD8+
CTL through the MHC class I processing and presentation
pathway. Selected genes would be screened in vitro for rec-
ognition by T. parva specific CTL. This report describes the
successful application of this novel approach to identify a
vaccine candidate antigen of T. parva that is the target of
schizont-specific CTL from immune cattle.
Results
Screening of genes selected from genome data
The preliminary sequence data of T. parva (Muguga) chro-
mosome 1 [13] was run through the gene finding pro-
grams GlimmerM [14] and Phat [15], and the proteins
encoded by the predicted T. parva genes subjected to a
variety of analyses to identify secreted or membrane-
anchored proteins. Fifty-five ORFs encoding candidate
antigens were selected for screening, of which 36 were suc-
cessfully cloned into pTargeT [16]. Each of the 36 ORFs
were transiently transfected into autologous immortalized
skin fibroblasts (iSF) and screened with a panel of sch-
izont specific polyclonal CTL lines or CTL clones gener-
ated from 13 T. parva immune cattle representing a
spectrum of bovine leukocyte antigen (BoLA) class I gen-
otypes. CTL from four animals (BW002, BW013, BW014
and D409) exhibiting high lytic activity against autolo-
gous schizont-infected lymphoblasts (Fig. 1A), all showed
significant IFN-γ ELISpot responses to iSF transfected with
cDNA Tp01_56 (Fig. 1B; p < 0.01). CTL lines from the
other nine cattle did not recognise iSF transfected with any
of the selected ORF's and no false positives were detected
during the screening (data not shown). The ability of CTL
to lyse iSF transfected with cDNA Tp01_56 was assessed
using a 51Chromium release assay (Fig. 1C). CTL exhib-
ited specific lysis against cDNA Tp01_56 transfected cells
and not against cells transfected with an irrelevant cDNA
cloned into the same vector. Lysis of cDNA Tp01_56
transfected cells by CTL was inhibited by pre-incubation
of target cells with a blocking mAb against MHC class I
(IL-A88; ILRI, Nairobi, Kenya). This observation together
with the inability of CTL to lyse cDNA Tp01_56 trans-
fected allogeneic cells suggested that the recognition and
lysis was MHC class I restricted. The gene encoding cDNA
Tp01_56 was assigned the name Tp2 (GenBank accession
number XM_760490).
Molecular characterisation of T. parva CTL target antigen 
Tp2
The Tp2 gene encodes 174 amino acid residues, has a cal-
culated mass of 19,141Da and an N-terminal signal pep-
tide with a predicted cleavage site between residues 23
and 24. The predicted mature protein contains twelve
cysteine amino acid residues suggesting that the tertiary
structure may be dependent on di-sulfide linkages. The
nucleotide and deduced amino acid sequences of the Tp2
gene are shown in Fig. 2A. Reverse transcriptase(RT)-PCR
revealed transcription of Tp2 in sporozoite, schizont and
piroplasm life-cycle stages of T. parva (Fig. 2B) and North-
ern blots detected the presence of ~1 kb transcript in sch-
izont and piroplasm RNA (Fig. 2C). Transcriptome
analysis of T. parva using massively parallel signature
sequencing indicated that Tp2 is expressed at a relatively
high level (1069 tpm) in the schizont stage [17]. The
cDNA clone was isolated from the schizont cDNA libraryImmunome Research 2007, 3:2 http://www.immunome-research.com/content/3/1/2
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Identification of antigen Tp2 Figure 1
Identification of antigen Tp2. (A) Lysis of autologous schizont infected cells by four T. parva-specific CTL lines capable of 
(B) specifically reacting to iSF transfected with 12 selected genes as assessed by IFN-γ ELISpot and (C) lysis of cDNA Tp01_56 
transfected-iSF. (A) Closed circles: BW002; open circles: BW013; closed squares: BW014; and open squares: D409. (B) IFN-γ 
responses to selected gene transfected iSF are presented as mean numbers of spot forming cells (SFC)/well. Black: BW002; 
white: BW013; grey: BW014; and hatched: D409. (C) Mean lysis of cDNA Tp01_56 transfected-iSF by CTL from the four cat-
tle. Closed circles: cDNA Tp01_56 transfected autologous iSF; open circles: Irrelevant gene transfected autologous iSF; closed 
squares: cDNA Tp01_56 transfected autologous iSF pre-incubated with an anti-MHC class I mAb; and open squares: cDNA 
Tp01_56 transfected allogeneic iSF.Immunome Research 2007, 3:2 http://www.immunome-research.com/content/3/1/2
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Nucleotide and deduced amino acid sequence of antigen Tp2 from T. parva Muguga Figure 2
Nucleotide and deduced amino acid sequence of antigen Tp2 from T. parva Muguga. (A) Tp2 is encoded by a single 
ORF of 525 bases translating into a protein of 174 amino acids. Transcription was assessed by (B) RT-PCR from RNA isolated 
from sporozoite (Sp), schizont (Sc) and piroplasm (Pi) developmental stages of T. parva and by (C) Northern blot hybridization 
against bovine (Bo), schizont (Sc) and piroplasm (Pi) RNA.Immunome Research 2007, 3:2 http://www.immunome-research.com/content/3/1/2
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contains a 1026 bp insert with 105 and 396 bp 5' and 3'
UTR's, respectively. Searches of protein and DNA data-
bases using BLAST identified a homolog of Tp2 in Theile-
ria annulata, a molecule described as a membrane-
associated antigen, TaD [18].
Mapping of CTL epitopes on Tp2
The CTL epitopes on Tp2 were mapped using a library of
12-mer overlapping synthetic peptides covering the full
length of the Tp2 protein. Recognition of Tp2 peptides
was assessed by IFN-γ ELISpot using autologous iSF as
antigen-presenting cells. Fig. 3A shows the results of
screening the Tp2 peptide library with CD8+ polyclonal
CTL lines from animal BW002, BW013, BW014 and CTL
clone T29.10 from animal D409. This allowed the identi-
fication of four epitope-containing regions. Minimal
length antigenic peptides were defined by screening all
possible 8-, 9-, 10- and 11-mers covering the regions iden-
tified above. The four minimal length antigenic peptides
recognized by CTL were 11-mers, SHEELKKLGML
(BW002) and KSSHGMGKVGK (BW013) and overlap-
ping 9-mers, FAQSLVCVL (D409) and QSLVCVLMK
(BW014) (data not shown).
Tp2 specific responses during protective immunity
As a prelude to directly testing the vaccine potential of the
Tp2 antigen in cattle, an experiment was conducted to
look for a Tp2-specific component within the protective
CD8+ T cell response following the challenge of three ECF
immune cattle with a lethal dose of sporozoites. All ani-
mals were solidly resistant to challenge, exhibiting only a
transiently detectable parasitosis and no fever (data not
shown). CD8+ T cells enriched from peripheral blood
responded to Tp2 antigenic peptides as measured by IFN-
γ ELISpot assay (Fig 4). Responses to the Tp2 antigenic
peptides were significantly greater than those to peptides
from other regions of Tp2 from day 9–11 post-challenge
(Fig. 4A–C; p < 0.05). Both the kinetics and magnitude of
the response correlate well with those previously
described for schizont-specific CTL in efferent lymph and
blood following challenge of immune animals [5].
Attempts to detect schizont and Tp2 specific cytotoxic
activity directly in the blood of cattle post-challenge failed
to demonstrate any significant lysis (data not shown).
However, 14 days post-challenge, BW002 PBMC stimu-
lated in vitro with autologous irradiated schizont- infected
cells and tested for cytotoxicity 7 days later exhibited sig-
nificant cytolytic activity against both schizont-infected
cells and iSF pulsed with the Tp2 antigenic peptide
SHEELKKLGML (Fig. 4D; p < 0.001). This finding is con-
sistent with the hypothesis that the CTL precursor fre-
quency in peripheral blood was too low to be measured
directly but could be increased to detectable levels follow-
ing a single re-stimulation in vitro.
Discussion
From the 986 predicted ORFs on chromosome 1, bioin-
formatics was used to select 55 genes encoding proteins
that could potentially access the host cell cytosol. From
the selected genes, 36 were successfully cloned into a
eukaryotic expression vector and screened for recognition
by schizont-specific CD8+  CTL derived from 13 cattle
immunised against T. parva by a live infection and treat-
ment immunization regime. One antigen, termed Tp2,
was identified by CTL from 4 different animals. Subse-
quent analysis has defined multiple CTL epitopes on this
molecule. Further evidence of the status of Tp2 as a bovine
CTL target antigen was provided by the temporal correla-
tion of detectable Tp2 specific CD8+ T cell responses with
the onset and clearance of T. parva schizont parasitosis fol-
lowing challenge infection.
The success of this approach has been underpinned by the
development of a sensitive CTL screening assay with
which to detect recognition of the selected antigens
expressed by transiently transfected antigen-presenting
cells. The current screening system is based on the same
principle as an assay developed to identify target antigens
of melanoma tumor cell specific human CTL [19,20]. This
system utilized the WEHI TNF-α bioassay to detect CTL
recognition of COS-7 cells co-transfected with pools of
melanoma cell cDNA and appropriate HLA class I cDNA
[19,20]. The limited number of cloned full length BoLA
class I cDNA and the relative insensitivity of WEHI cells to
bovine TNF-α meant that an alternative antigen-present-
ing cell and read-out system were required to screen for T.
parva antigens with bovine CTL. Autologous bovine skin
Mapping of CTL epitopes on Tp2 Figure 3
Mapping of CTL epitopes on Tp2. Eighty-four 12-mer 
peptides overlapping by ten amino acids encompassing the 
full length of Tp2 were screened with four CTL and recogni-
tion assessed by IFN-γ ELISpot. Responses are presented as 
mean numbers of spot-forming cells (SFC)/well. Closed cir-
cles: BW002; open circles: BW013; closed squares: BW014; 
and open squares: D409.Immunome Research 2007, 3:2 http://www.immunome-research.com/content/3/1/2
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fibroblasts stably transfected with the large T antigen of
SV40 provided a system that did not limit the BoLA hap-
lotypes that could be recruited for screening, avoided the
practical limitations of working with primary cell lines
and gave significantly enhanced expression of proteins
following transient transfection. All bovine schizont-spe-
cific CTL lines tested to date secrete IFN-γ and detection of
this cytokine using an ELISpot assay [21] provided an
extremely sensitive read-out to replace the TNF bioassay.
Screening of the selected genes with schizont-specific CTL
identified cDNA Tp01_56 as encoding a target antigen.
We subsequently confirmed that recognition was MHC
class I restricted and led to lysis of the expressing cell.
Despite the relative inefficiency of transient transfection,
51Chromium release assays could be performed to con-
firm MHC class I restricted lysis of Tp2 transfected cells.
A strength of this approach is the ability to use schizont-
specific CTL populations that have been maintained in
the laboratory to screen for antigens. However, although
CTL lines present a sensitive and exquisitely specific
screening tool there is the possibility that the antigens that
will be identified will be the most immunodominant as a
result of biases introduced during the in vitro restimula-
tion procedure that is required to maintain the lines. The
antigens identified may represent those that are well
expressed in schizont-infected cell lines in vitro and may
have little relevance to protective CTL responses in vivo. As
a prelude to testing this hypothesis directly with challenge
protection experiments, an experiment was conducted to
look at Tp2-specific CD8+ T cell responses following the
challenge of immune animals with a lethal dose of sporo-
zoites. Both, the kinetics of the response, observed from
Ex vivo Tp2 specific CD8+ T cell responses following challenge of immune cattle Figure 4
Ex vivo Tp2 specific CD8+ T cell responses following challenge of immune cattle. Tp2 specific CD8+ T cell 
responses following challenge of T. parva immune cattle. Responses of three cattle, (A) BW014, (B) BW013 & (C) BW002, 
were measured longitudinally by IFN-γ ELISpot and responses are presented as mean numbers of spot-forming cells (SFC)/1 × 
106 CD8+ T cells. Closed circles: Tp2 antigenic peptide and open circles: control peptide. (D) Cytotoxic activity of stimulated 
BW002 PBMC was assessed 14 days post-challenge. Closed circles: Autologous schizont-infected cells; closed squares: Tp2 
antigenic peptide pulsed iSF; open squares: Control peptide pulsed iSF; and open circles: Allogeneic schizont infected cells.Immunome Research 2007, 3:2 http://www.immunome-research.com/content/3/1/2
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day 9 post-challenge, and the magnitude of the response,
with a responder frequency of 1/500, correlates very well
with that previously described for schizont-specific CTL in
efferent lymph and peripheral blood following challenge
of immune cattle [5] and provides evidence to support a
role for Tp2 in protective immunity. To this end, in a pre-
liminary immunization and challenge cattle experiment
evaluating Tp2 and other candidates, it was demonstrated
that this CTL target antigen has potential for vaccine
exploitation [16].
The ultimate vaccine against T. parva will almost certainly
need to incorporate multiple antigens and epitopes in
order to confer protection in the genetically diverse out-
bred cattle population exposed to challenge by antigeni-
cally diverse parasite populations in the field. This study
demonstrates proof of concept for the application of a
genomic approach for identification of candidate antigens
for inclusion in vaccines designed to induce CTL-based
protection. This approach compliments the random
screening of cDNA libraries that has successfully been
applied to identify additional CTL target antigens from T.
parva  [16] and human melanomas [19,20]. The major
challenge remains the formulation and delivery of these
antigens in a manner that adequately primes protective
memory CD8+ T cell populations in vivo.
Conclusion
This study validates the exploitation of genomic data to
identify vaccine candidate antigens from a complex hae-
moprotozoan parasite using CTL derived from the natural
ruminant host. Extension of this approach to the com-
plete genome of T. parva using CTL restricted by addi-
tional bovine haplotypes is likely to result in
identification of further vaccine candidates. The identifi-
cation of an antigen containing multiple CTL epitopes
makes Tp2 an attractive candidate for inclusion in a CTL
targeted sub-unit vaccine and also for the study of poly-
morphism in CTL epitopes in cattle and Cape buffalo
(Syncerus caffer). An in-depth evaluation of this antigen in
cattle involving a range of antigen delivery technologies
perceived to have the potential to induce bovine CTL is in
progress in order to assess the immunogenicity and pro-
tective efficacy of Tp2 against clinical East Coast fever
Methods
Generation of selected gene list
Preliminary contigs of the T. parva genome were searched
against a non-redundant database of proteins extracted
from GenBank. The search results were used to produce a
set of putative T. parva genes that encoded highly con-
served eukaryotic genes. This set of genes was comple-
mented with a number of full length genes isolated from
a cDNA library made from purified schizonts and were
used to train the gene finding programs GlimmerM [14]
and Phat [15], which were subsequently run against all of
the preliminary contigs to produce gene models for the
entire preliminary genome sequence. The proteins
encoded by the predicted T. parva genes on chromosome
1 were searched against a non-redundant protein database
using WU-BLAST [22], and predictions of signal peptides
and signal anchors [23] and transmembrane domains
[24] analysed. The results were reviewed and a set of 55
genes encoding candidate antigens was selected for clon-
ing and screening [16].
Cloning of selected genes
Open reading frames (ORFs) less than 3.1 kb were suc-
cessfully amplified by OneStep RT-PCR kit (QIAGEN Ltd.,
Crawley, UK) using RNA purified from T. parva (Muguga)
schizont-infected lymphoblasts. Thermal cycles were:
Genes up to 1 kb: 50°C 30 minutes; 95°C 15 minutes;
94°C 30 seconds; 55°C 30 seconds; 72°C 1 minute; 35
times from 94°C cycle and finally 72°C 10 minutes.
Genes between 1 and 2 kb: 50°C 30 minutes; 95°C 15
minutes; 94°C 1 minute; 55°C 1 minute; 72°C 1 minute;
35 times from 94°C cycle and finally 72°C 10 minutes.
Genes between 2 and 3 kb: 45°C 30 minutes; 95°C 15
minutes; 94°C 10 seconds; 55°C 1 minute; 68°C 3 min-
utes; 35 times from 94°C cycle and finally 68°C 10 min-
utes. Amplified genes were purified from agarose gels by
QIAquick Gel Extraction kit (QIAGEN) and cloned into
eukaryotic expression T-vector pTargeT (Promega, Madi-
son, WI, USA). Ligated samples were electroporated into
JM109, and colonies were screened by PCR using gene
specific internal forward primers and vector specific
reverse primer (5'GAGCGGATAACATCACACAGG3').
Positive colonies were cultured in 2 ml and plasmids puri-
fied by QIAprep Spin Miniprep kit (QIAGEN) and
sequenced by ABI PRISM 377 DNA sequencer (Applied
Biosystems, Foster City, CA, USA). Although 51 of 55
selected genes were amplified, 36 were cloned successfully
in pTargeT [16]. Some of the genes were consistently
cloned in wrong orientation suggesting the gene products
were toxic to E. coli. Some genes were amplified by the
reverse primer only and missed the 5' end.
Analysis of the temporal expression of Tp2
Total RNA from sporozoites, schizonts and piroplasms
was reverse-transcribed into ss-cDNA by reverse tran-
scriptase using oligo-(dT) as primer following the recom-
mendation of the supplier (Invitrogen). After removal of
RNA complementary to the cDNA by treatment with
RNase H and purification with phenol-chloroform, the ss-
cDNA was PCR-amplified in the presence of specific prim-
ers used to generate the Tp2 ORF (5'-ATGAAATT-
GGCCGCCAGA-3' and 5'-
CTATGAAGTGCCGGAGGCTTCTCC-3'). Northern blots
of RNA from the schizont and piroplasm stages of T. parva
were probed with the Tp2 ORF DNA fragment. This probeImmunome Research 2007, 3:2 http://www.immunome-research.com/content/3/1/2
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was also used to screen a schizont cDNA library and
restriction enzyme analysis was performed by digestion
with Eco RI and Bam HI.
Infection and treatment immunization of cattle and 
generation of CTL
All animal experimentation was reviewed and approved
by the ILRI Institutional Animal Care and Use Committee.
Four Boran (Bos indicus), 1 Jersey (Bos taurus), 1 Holstein-
Friesian (Bos taurus) and 4 crossbreds, selected on the
basis of BoLA type, were immunized against T. parva
Muguga stock, challenged after 3 months and schizont-
specific polyclonal CTL lines and clones established as
described [16].
Transient transfection of immortalized skin fibroblasts
Immortalized skin fibroblasts (iSF) were transfected in
96-well plates with cDNA clones (100 ng/well) using
Fugene-6 (Roche Diagnostics GmbH, Mannheim, Ger-
many) and cultured for 24 hours.
IFN-γ ELISpot and 51Chromium release assays
Transfectants were co-cultured with schizont-specific CTL
and recognition assessed using an IFN-γ ELISpot assay
[16]. Transfectants and schizont-infected cells were
labelled with 51Chromium (Amersham Biosciences
Europe GmbH, Freiburg, Germany) and lysis by schizont-
specific CTL lines assessed [25].
Identification of CTL epitopes with synthetic peptides
A peptide library of Tp2 was generated that contained
every 12 mer, 11 mer, 10 mer and 9 mer offset by 2 amino
acids from the protein sequence (Cleaved PepSet; Mimo-
topes, Clayton, Australia). Peptides were prepared by
truncations of 12 mers at the N-terminus and supplied
lyophilized with each tube containing a nominal 12 mer
and the 9, 10, 11 mer truncations with the same C-termi-
nus. Peptides were dissolved in 400 μl 50% (v/v) DNA
synthesis grade acetonitrile/water (Applied Biosystems).
Peptides were further diluted to 10 μg/ml in complete
RPMI-1640 and 10 μl added to triplicate wells of an ELIS-
pot plate. Autologous iSF were adjusted to a density of 4 ×
105/ml and 50 μl added to wells containing peptides. The
plates were incubated at 37°C for 1 hour before 50 μl of
CTL at a density of 2 × 105/ml were added to each well.
Plates were incubated and developed as described above.
Based on the results of screening the peptide library, indi-
vidual 8, 9, 10 or 11 mer peptides were synthesized and
tested as described above. Peptide-pulsed iSF were pre-
pared as targets for 51Chromium release assays by over-
night incubation with peptide at 1 μg/ml in complete
DMEM. Cells were harvested, labelled and assayed as
described above.
Ex vivo detection of Tp2 specific CD8+ T cell responses
Immune cattle, BW002, BW013 and BW014, whose sch-
izont-specific CTL had recognized Tp2, were challenged
with a lethal dose of T. parva (Muguga) sporozoites and
bled daily from day 6 to 13 post-challenge. CD8+ T cells
and CD14+  monocytes were purified from PBMC by
MACS magnetic cell sorting according to the manufac-
turer's instructions (Miltenyi Biotec, Gergisch Gladbach,
Germany). CD8+ T cells were sorted indirectly using a
monoclonal antibody specific for bovine CD8 (IL-A105;
ILRI, Nairobi, Kenya) followed by incubation with goat
anti-mouse IgG microbeads (Miltenyi Biotec). CD14+
monocytes were sorted directly by incubation with CD14
microbeads (Miltenyi Biotec). CD8+ T cells (2.5 × 105/
well) and CD14+ monocytes (2.5 × 104/well) were added
to IFN-γ ELISpot plates containing Tp2 peptides (1 μg/ml
final concentration) and were incubated and developed as
described [21]. To recall Tp2 specific CTL responses,
PBMC were stimulated with autologous infected lym-
phoblasts 14 days post-challenge, viable cells were har-
vested 7 days post-stimulation and lytic activity against
infected lymphoblasts and Tp2 peptide pulsed iSF
assessed as described above.
Statistical analysis
Analysis of variance (ANOVA) was used for the analysis of
fixed effects on different traits using SAS Release 8.2 (SAS
Institute Inc., Cary, USA).
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